The future of infection management won't be built by science alone
Increasing antimicrobial resistance (AMR) is one of the defining healthcare challenges of our generation. According to the World Health Organisation, Bacterial AMR is already linked to more than 4.7 million deaths annually. Without urgent action, AMR could cause up to 39 million deaths between 2025 and 2050, and cost the global economy $7.7 trillion by 2035, disproportionately affecting low- and middle-income countries.
Innovation in MedTech sits at the heart of the solution. Breakthrough innovations are emerging across rapid diagnostics, bacteriophage therapies, microbiome medicines, biologics, vaccines and connected health technologies. Yet many struggle to move beyond promising research because development, validation, manufacturing and adoption remain major barriers.
CPI has state-of-the-art expertise and facilities to help innovators accelerate progress, reduce development risk and build the capabilities needed to bring the next generation of AMR solutions to market.
Moving antimicrobial resistance innovation beyond the lab
There's no shortage of promising innovation in AMR. Researchers are developing novel diagnostics, from rapid molecular tests, community-based testing or devices that harness AI-insights, to treatments such as microbiome therapies, bacteriophages, vaccines and novel biologics. These are capable of transforming how resistant infections are detected, prevented and treated.
The remaining challenge is translating discovery into industrial reality, and many innovations fail because they can’t be validated, manufactured, scaled or adopted efficiently enough to create real-world impact.
That's where CPI helps.
We work with innovators to accelerate development, reduce technical risk and overcome scale-up barriers. By generating data, evidence and validation early, we help organisations make informed development and investment decisions, while building the manufacturing capability and partnerships needed to bring AMR innovations closer to patients.
Our capabilities
We innovate with organisations across pharma and MedTech, bringing together expertise in diagnostics, advanced therapeutics, connected health technologies, bioprocessing and manufacturing to support the development and scale-up of solutions to tackle AMR.
We support:
Technical risk reduction.
Technology validation.
Prototype development.
Assay development.
Process optimisation.
Scale-up strategy.
Regulatory readiness.
Evidence generation.
Areas of expertise
Accelerate your AMR innovation with CPI
If you’re developing a new diagnostic, antimicrobial therapy or infection management technology, CPI can help you overcome technical challenges, reduce development risk and progress towards scalable manufacturing and commercialisation.


